Conference Abstracts

The browser you are using will not work with the contents of this page, we recommend that you update to a newer browser or check to make sure that JavaScript is enabled.

Incidence and Predisposition to WM

Trend and Geographic Variations in the Incidence of Waldenström s Macroglobulinemia in the United States over 17 Years from 1988 to 2004. Michael Wang, Yuhong Zhou, Haijun Wang, Qing Yi, Yanxia Zhang, Raymond Alexanian, Larry Kwak, Xin Du Lymphoma/Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Oncology, Fudan University, Shanghai, China; Epidemiology, University of Texas School of Public Health, Houston, TX, USA.

Prevalance of MGUS and Incidence of WM in Japan. Masako Iwanaga, M.D., M.P.H. Department of Molecular Medicine & Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JAPAN.

IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström’s Macroglobulinemia (SWM). Robert A. Kyle, MD; Joanne T. Benson, BA; Dirk Larson, MS; Terry Therneau, PhD; Angela Dispenzieri, MD; Lee Joseph Melton III, MD; S. Vincent Rajkumar, MD Mayo Clinic, Rochester, MN, USA.

Familial Predisposition to Monoclonal Gammopathy of Unknown Significance, Waldenstrom's Macroglobulinemia and Multiple Myeloma. Helga M. Ögmundsdóttir, Helga K. Einarsdóttir, Hlíf Steingrímsdóttir, Vilhelmína Haraldsdóttir. Faculty of Medicine, University of Iceland; Department of Clinical Haematology, Landspitali Universtity Hospital, Reykjavik, ICELAND.

The relationship between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance: studies of high-risk families. Mary L. McMaster, Lynn Goldin, and Gyorgy Csako Genetic Epidemiology Branch, Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia patients: A population-based study in Sweden. Sigurdur Y Kristinsson, Magnus Björkholm, Lynn R Goldin, Mary L McMaster, Ingemar Turesson, and Ola Landgren Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden; National Cancer Institute, NIH, Bethesda, Maryland, USA; Department of Medicine, Section of Hematology, Malmö University Hospital, Malmö, SWEDEN.

Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with Familial Waldenström’s Macroglobulinemia. Z. R. Hunter, L. Ioakimidis, J. Soumerai, C. J. Patterson, L. Xu, X. Leleu, B. T. Ciccarelli, A. Sacco, S. Adamia, E. Hatjiharissi, S. P. Treon. Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA, USA.

Genetic Basis and Pathogenesis of WM and IgM Related Disorders

Origins of Waldenström’s macroglobulinemia. Linda M. Pilarski, Sophia Adamia, Amanda Reichert, Julia Kirshner, Steven P. Treon, Tony Reiman, Andrew R. Belch Dept. Oncology, University of Alberta and Cross Cancer Institute, CANADA.

CD27 in defining B-cell memory origins in WM. Surinder S. Sahota, Gavin Babbage, Nicola Weston, Bell Cancer Sciences Division, School of Medicine, University of Southampton, Southampton, UNITED KINGDOM.

Cytogenetic abnormalities in a cohort of 120 untreated patients enrolled in the WM1 trial. Trisomy 4 prevalence. F. Nguyen-Khac, Unite de Cytogenetique Hematologique, Service d'Hematologie Biologique, Groupe Hospitalier Pitie-Salpetriere, Pavillon Laveran, 47-83 Bd de l'Hopital, 75013 Paris, FRANCE.

Cytogenetic aberrations in polyneuropathy associated with IgM monoclonal gammopathy. Eurelings M, Lokhorst HM, Notermans NC, Krijtenburg PJ, Kessel B, Eleveld MJ, Bloem A, Wokke JH, Poot M, Buijs A, NETHERLANDS.

NF-kB abnormalities in Waldenström’s Macroglobulinemia. Esteban Braggio, PhD., Rafael Fonseca, MD, Mayo Clinic, Scottsdale, AZ, USA.

Immunoglobulin Gene Rearrangements in Waldenström’s macroglobulinemia. Ramón García-Sanz, Patricia Martín-Jiménez, Enrique M. Ocio, María E. Sarasquete, Marcos Gonzalez, Jesus F. San Miguel. Hematology Department. University Hospital of Salamanca, SPAIN.

High-throughput microRNA profiling: Identification of miRNAs with a potential pathogenetic role in Waldenström's macroglobulinemia. Adamia S., Amin S., Patterson C., Moreau P., Minvielle S., Li C., AvetLoiseau H., Anderson K.C., Munshi N.C. and Treon S.P. Dana-Farber Cancer Institute, and Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA; Hematology Department, Hopital de Nantes, Nantes, FRANCE.

5-Azacytidine inhibits the mammalian target of rapamycin complex 1 signal and induces apoptosis in Waldenström’s macroglobulinemia. Lian Xu, B. Ciccarelli, E. Hatjiharissi, S. Adamia, Y. Zhou, J. Sun, G. Yang, H. Tseng, X. Liu, Z. Hunter, L. Ioakimidis, R. Manning, C. Patterson and S.P. Treon. Bing Center for Waldenström's Macroglobulinemia, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts USA.

Role of CCL5 and Interleukin-6 in the Biology of Waldenström’s macroglobulinemia. Stephen M. Ansell, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Role of Hepatitis C In Waldenström’s macroglobulinemia. Thomas Giordano, Department of Medicine, Baylor College of Medicine, and the Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.

Chronic immune stimulation and subsequent Waldenström's macroglobulinemia. Ola Landgren, Gloria Gridley, Eric A. Engels, Mary L. McMaster, Sigurdur Y. Kristinsson, Ingemar Turesson, Magnus Björkholm, Jill Koshiol. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Medicine, Karolinska Institutet, Hematology Center, Karolinska University Hospital, Stockholm, SWEDEN; Department of Medicine, Section of Hematology, Malmo University Hospital, Malmo, SWEDEN.

Micro-Environment & Immune Regulation in WM

Gene Expression Profiling of Malignant and Microenviromental Cells in Waldenström’s Macroglobulinemia: Therapeutic implications. Evdoxia Hatjiharissi, Constantine S. Mitsiades, Cheng Li, Lian Xu, Bryan T. Ciccarelli, Aldo Roccaro, Zachary Hunter, Xavier Leleu, Leukothea Ioakimidis, Christopher J. Patterson, Irene Ghobrial and Steven P. Treon Bing Center for Waldenström's Macroglobulinemia, Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Angiogenesis in Waldenström's Macroglobulinemia. Evangelos Terpos, Anna Tasidou, Efstathios Kastritis, Evangelos Eleftherakis-Papaiakovou, Maria Gavriatopoulou, Magda Migkou, Meletios-Athanassios Dimopoulos Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece & Department of Hematopathology, Evangelismos Hospital, Athens, GREECE.

Immunophenotypic comparison of IgM MGUS and Waldenström’s macroglobulinemia. Enrique M. Ocio, Jennifer Alonso, Bruno Paiva, Ramón García-Sanz, Alberto Orfao, Belén Vidriales, Jesús F. San-Miguel Hospital Universitario de Salamanca. Centro de Investigación del Cáncer. University of Salamanca, Salamanca, SPAIN.

TH17 pathway and associated pro-inflammatory cytokines in Waldenström's macroglobulinemia (WM). Rao Prabhala, Dheeraj Pileru, Steven P. Treon and Nikhil C. Munshi. Dana Farber Cancer Institute, Boston VA Healthcare System, Harvard Medical School, Boston, MA, USA.

T cell immunity in Waldenström’s Macroglobulinaemia and Myeloma. D.E. Joshua, Ross D. Brown, Daniel M. Y. Sze Suilin, Mo J. Gibson, and P. J. Ho. Institute of Haematology, Royal Prince Alfred Hospital, Sydney, AUSTRALIA.

Prognistic, Predictive, and Response Markers in WM

International Waldenström Macroglobulinemia Prognostic Index Project. Pierre Morel, Olivier Tournilhac, Jérôme Tamburini, Alain Duhamel, Jacques Vargaftig, Bénédicte Hivert and Veronique Leblond. Services d’Hématologie des Hôpitaux de Lens, Clermont Ferrand, Pitié-Salpêtrière, Paris. Centre d’Etude et de Recherche en Informatique Médicale de Lille, FRANCE.

Prognostic relevance of 6q deletion in Waldenström’s Macroglobulinemia. Chang H, Qi C, Trieu Y, Jiang A, Xu W, Young KH, Chesney A, Jani P, Wang C, Reece D, Chen C. University Health Network, Toronto. University of Wisconsin, USA. Sunnybrook Health Sciences Center, Toronto. Thunder Bay Health Sciences Center, Ontario. Mount Sinai Hospital, Toronto, CANADA.

Plasma cell differentiation in indolent lymphomas originated from marginal zones. Jean Feuillard, Centre Hospitalier Universitaire (CHU) Dupuytren and Faculté de Médecine, Université de Limoges, FRANCE.

Prognostication in young and elderly patients with WM. E. Kastritis, K. Zervas, P. Repoussis, E. Michali, A. Zomas, A. Simeonidis, E. Terpos, S. Delimbassi, A. Vassou, D. Gika, M.A. Dimopoulos, on behalf of the Greek Myeloma Study Group, Athens, GREECE.

Complexities of assessing response in WM. Roger Owen, HMDS Laboratory, The Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM.

Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as, plasmapheresis, in patients with Waldenström's Macroglobulinemia. B. T. Ciccarelli, G. Yang, E. Hatjiharissi, J. D. Soumerai, Z. R. Hunter, L. Ioakimidis, C. J. Patterson, R. J. Manning, L. Xu, S. Adamia, S. P. Treon; Dana-Farber Cancer Institute, Boston, MA, USA.

Treatment of Waldensroms Macroglobulinemia

Rituximab based therapies in Waldenström's macroglobulinemia. M.A. Dimopoulos, MD, E. Kastritis, MD, M. Gavriatopoulou, MD, M. Migkou, MD, M. Roussou, MD , E. Eleftherakis-Papaiakovou, MD, E. Terpos, MD. Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, GREECE.

Maintenance rituximab in indolent lymphoma. Michele Ghielmini, Oncology Institute of Southern Switzerland and Swiss Group for Clinical Cancer Research, Bellinzona, SWITZERLAND.

Fludarabine-based Combination therapies for Waldenströms macroglobulinemia. Enrica Morra, Dept. of Hematology, Niguarda Ca’ Granda Hospital, Milano, ITALY.

Long Term Responses to Fludarabine and Rituximab in Waldenström's Macroglobulinemia. Andrew Branagan, Leukothea Ioakimidis, Jacob Soumerai, Christopher Patterson, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, T. Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby, Steven P. Treon. Dana-Farber Cancer Institute, Boston, MA, USA; McMaster University, Hamilton, Ontario, CANADA, Interbalkan Hospital, Pylaia, GREECE, University of Maryland, Greenbaum Cancer Center, Baltimore MD, USA; Centre for Medical Oncology, Barts and the London School of Medicine, London, UNITED KINGDOM; Service d'Hematologie Clinique, Lens, FRANCE; Rocky Mountain Cancer Center, Denver, CO, USA; Rush University Hospital, Chicago, IL, USA; Hematology Center, Karolinska Institutet, Stockholm, SWEDEN.

Bortezomib in Relapsed/Refractory Waldenström’s macroglobulinemia. Christine Chen, C. Tom Kouroukis, Darrell White, Michael Voralia, Edward Stadtmauer, A.Keith Stewart, John J.Wright, Jean Powers, Wendy Walsh, Elizabeth Eisenhauer Princess Margaret Hospital, University of Toronto, Ontario, CANADA.

Bortezomib alone and in combination with Rituximab in patients with Waldenström’s Macroglobulinaemia. A Rohatiner, A Agathocleous, S Rule, P Johnson, J Radford, S Strauss, A Lister CR-UK Medical Oncology Unit, St. Bartholomew’s Hospital, London. Dept. of Haematology, Derriford Hospital, Plymouth. CR-UK Clincal Centre, Southampton General Hospital, Southampton. CR-UK Dept. of Medical Oncology, Christie Hospital and University of Manchester, Manchester, UNITED KINGDOM.

Primary Therapy of Waldenström’s Macroglobulinemia with Bortezomib, Dexamethasone and Rituximab: Results of WMCTG Clinical Trial 05-180. S.P. Treon, L. Ioakimidis, J.D. Soumerai, C.J. Patterson, M.A. Willen, J. Matous, J. Mattern II, J. Diener, G. Keogh, T.J. Myers, A. Birner, A. Boral, and I. Ghobrial. Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Boston MA; New York Hematology and Oncology, Latham NY; Rocky Mountain Cancer Center, Denver CO; Virginia Oncology Associates, Newport News VA; Littleton Regional Hospital, Littleton NH; Charleston Hematology Oncology, Charleston SC; and Millenium Pharmaceuticals, Inc., Cambridge MA, USA.

The Emerging Role of Histone Deacetylase Inhibitors in Waldenström‘s Macroglobulinemia. Owen A. O’Connor, The New York Presbyterian Hospital, Columbia University, New York, N.Y., USA.

Novel Agents for Treatment of WM

CHOP versus R-CHOP in Waldenström´s macroglobulinemia (WM). C. Buske for the German Low Grade Lymphoma Study Group (GLSG), Munich, GERMANY.

Bendamustine plus Rituximab versus CHOP plus Rituximab in the First-Line-Treatment of Patients with Waldenström’s disease – First interim Results of a Randomized Phase III Study of the Studygroup Indolent Lymphomas (StiL). Mathias J Rummel, University Hospital, Giessen, Germany, Ulrich von Gruenhagen, Praxis Cottbus, Germany, Norbert Niederle, Klinik Leverkusen, Harald Ballo, Praxis Offenbach, Eckhart Weidmann, Krankenhaus Nordwest, Manfred Welslau, Praxis Aschaffenburg, Gerhard Heil, Krankenhaus Luedenscheid, Christina Balser, Praxis Marburg, Heinz A Duerk, Hamm, Martina Stauch, Praxis Kronach, Dorothea Kofahl-Krause, MHH Hannover, Ulrich Kaiser, Hildesheim, Wolfgang Knauf, Praxis Frankfurt and Wolfram Brugger, MD, Hematology/Oncology, Schwarzwald-Baar Clinic, Voehrenbacherstr. 23, Villingen, 78050, GERMANY.

Regulation of the PI3K/mTOR pathway in Waldenström’s Macroglublinemia (WM). Irene M. Ghobrial, Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.

Antibody-based Therapeutics Targeting the TNF Superfamily Member CD70. Iqbal S. Grewal, Department of Preclinical Therapeutics, Seattle Genetics, Inc., Bothell, WA, USA.

Targeting CD40 in Waldenström’s Macroglobulinemia (WM). Ranjana Advani, Stanford University Medical Center, Palo Alto CA, USA.

Novel Proteasome Inhibitor in Waldenström’s macroglobulinemia. Aldo Roccaro, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Applying the Lessons Learned from the Treatment of Multiple Myeloma to Waldenström’s Macroglobulinemia. Kenneth C. Anderson, Dana Farber Cancer Institute. Boston, MA, USA.

Transplant Therapy of WM

Fludarabine for Waldenström’s macroglobulinemia (WM) – A 10 year follow-up of Southwest Oncology Group (SWOG) directed Intergroup trial S9003 Bart Barlogie, Madhav Dhodapkar and John Crowley for SWOG; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Yale University, Brookhaven, CT; Cancer Research and Statistics, Seattle, WA.

Haematopoietuc stem cell transplantation for Waldenström’s macroglobulinemia (WM) patients. H. Kyriakou, on behalf of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT), London, UNITED KINGDOM.

Evidence for GVWM following mini-allo in WM. David G. Maloney and Larry D. Anderson, Fred Hutchinson Cancer Research Center (FHCRC) and the University of Washington, Seattle, WA, USA.

Stem cell transplantation for IgM amyloidosis and IgM multiple myeloma. Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Kumar S, Hayman, SR, Buadi F. Mayo Clinic, Rochester, Minnesota, USA.

Therapy Related Complications in WM

Incidence of disease transformation and development of MDS/AML in 165 patients with Waldenström’s Macroglobulinemia (WM) treated with fludarabine (F) -based regimen in three studies (French cooperative group on CLL/WM) Veronique Leblond, Jerome Tamburini, Vincent Levy, Sylvain Choquet, Anne_Laure Taksin, Frederic Maloisel, and Pierre Morel Hematology, Pitié-Salpêtrière Hospital, Paris, FRANCE.

Increased incidence of Transformation and Myelodysplasia/Acute Leukemia in patients with Waldenström’s Macroglobulinemia treated with Nucleoside Analogues. Xavier Leleu and Jacob Soumerai, Aldo Roccaro, Evdoxia Hatjiharissi, Zachary R. Hunter, Robert Manning, Bryan T. Ciccarelli, Antonio Sacco, Leukothea Ioakimidis, Sophia Adamia, Anne-Sophie Moreau, Christopher J. Patterson, Irene M. Ghobrial, and Steven P. Treon. Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, FRANCE and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Success Rates of Autologous Stem Cell Collection in Patients with Waldenström Macroglobulinemia. Sheeba K. Thomas, M.D., Chitra Hosing, M.D., Kay B Delasalle, B.S., Maria B. Gavino, R.N., Uday R. Popat, M.D., Muzaffar H. Qazilbash, M.D., Sergio A. Giralt, M.D., Donna M. Weber, M.D. and Raymond Alexanian, M.D., Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, USA.

The Pro’s and Con’s of initial treatment with purine-nucleoside analogue-based combination therapies in patients with Waldenström macroglobulinemia. John Seymour, Peter MacCallum Cancer Centre, Melbourne, Australia.

Disease Related Morbidities in WM

Waldenström’s and the Nervous System: “Bing Neel” revisited. Fred Hochberg, Massachusetts General Hospital, Pappas Center for Neuro Oncology, Boston, MA, USA.

Antigenic determinants in IgM Paraproteinemic Neuropathies. Eduardo Nobile-Orazio PhD, Department of Neurological Sciences, Milan University, 2nd Neurology Service, Humanitas Clinical Institute, Milan, ITALY.

Treatment of Peripheral Neuropathies Associated with IgM Monoclonal Gammopathies. Todd D. Levine, Phoenix Neurological Associates, Phoenix, AZ, USA.

Cutaneous Manifestations of Waldenström’s Macroglobulinemia. JP Fermand, B Asli and JC Brouet, Immuno-Hematology unit, Hôpital Saint Louis, 75010, Paris, FRANCE.

Cold Agglutinin mediated Autoimmune Hemolytic Anemia in Waldenström’s macroglobulinemia. Sigbjorn Berentsen Department of Medicine, Haugesund Hospital, Haugesund, and Institute of Medicine, University of Bergen, Bergen, NORWAY.

Hyperviscosity Syndrome and Cryoglobulinemia. Marvin J. Stone, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA.

Hyperviscosity Related Retinopathy in Waldenström’s Macroglobulinemia. Menke MN, Feke GT, McMeel JW ,Treon SP; Schepens Retina Associates Foundation, Boston, USA; Harvard Medical School, Boston, USA; Department of Ophthalmology, University of Zurich, Switzerland; Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Boston, USA.

Biology and therapy of amyloidosis associated with IgM monoclonal protein. Giampaolo Merlini, Giovanni Palladini, Center for Research and Treatment of Systemic Amyloidosis, Fondazione IRCCS Policlinico San Matteo, University of Pavia, ITALY.

Young Investigator Poster Sessions

The Novel Hydroxamic Acid-Derived HDAC Inhibitor, LBH589, Induces In Vitro Antitumor Activity in Waldenström’s Macroglobulinemia. Xiaoying Jia , Aldo M. Roccaro , Abdelkareem Azab , Hai T. Ngo , Antonio Sacco , Molly R Melhem , Feda Azab , Judith Runnels , Nicolas Burwick , Phong Quang , Hemanuel N. Husu,Teru Hideshima , Xavier Leleu and Irene M. Ghobrial . Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Service des Maladies du Sang et Laboratoire d'Immunologie, CHRU, Lille, FRANCE.

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström’s Macroglobulinemia. J.Y. Sun, L. Xu, H.Y. Tseng, B. Ciccarelli, M. Fulciniti, E. Hatjiharissi, Y. Zhou, G. Yang, X. Liu, T. Ioakimidis, P. Sheehy, R. Manning, C. Patterson, N. Munshi, O. O’Connor, S.P. Treon. Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; and Columbia University, New York, NY, USA.

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenström’s macroglobulinemia. Hai T. Ngo, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Acquired von Willebrand syndrome and von Willebrand factor abnormalities in Waldenström’s Macroglobulinemia. B. Hivert, C. Caron, A. Duhamel, J. Goudemand and P. Morel, Hospitalier Schaffner, Lens, FRANCE.

Is SDF1(-801 GA) polymorphism a new genetic prognostic for survival after treatment initiation in Waldenström’s macroglobulinemia (WM)? S. Poulain S, M. Ertault, X. Leleu, V. Coiteux, J. Fernandes, L. Stalnikiewicz, P. Duthilleul, P. Morel. CH de VALENCIENNES, FRANCE, CH de LENS, FRANCE , CHRU de LILLE, FRANCE.

Toward a Proteomic Specific WM (Waldenström’s macroglobulinemia) Entity. Laurent Vallat , Aurore Perrot, Cedric Pionneau4, Frederic Jacob, Nabih Azar, Martine Brissard, Frederic Davi, François Lemoine, Lucile Musset, Hélène Merle-Béral and Veronique Leblond Department of Biological Hematology, Pitie-Salpetriere Hospital, France Department of Clinical Hematology, Pitie-Salpetriere Hospital, France Department of Immunology, Pitie-Salpetriere Hospital, France Post-Genomic Platform P3S, Pitie-Salpetriere Hospital, University of Paris VI, France INSERM U543, UPMC University of Paris VI, FRANCE.

Comparative Outcomes following CP-R, CVP-R and CHOP-R in patients with Waldenström’s Macroglobulinemia. Ioakimidis L, Patterson CJ, Soumerai JD, Manning RJ, Sheehy P, Treon SP. Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Fludarabine based combinations are highly effective as first-line or salvage treatment for patients with Waldenström’s Macroglobulinemia. S Peinert, CS Tam, HM Prince, J Scarlett, MM Wolf, EH Januszewicz, D Westerman, JF Seymour Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, AUSTRALIA; Department of Haematology, St Vincent's Health Melbourne, Fitzroy, AUSTRALIA; Gippsland Cancer Care Centre Latrobe Regional Hospital, Traralgon, AUSTRALIA.